Litigation Details for GENENTECH, INC. v. CELLTRION, INC. (D.N.J. 2018)

GENENTECH, INC. v. CELLTRION, INC. (D.N.J. 2018)

Docket		Date Filed	2018-01-12
Court	District Court, D. New Jersey	Date Terminated	2018-11-01
Cause	15:1126 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand	Plaintiff	Referred To	Karen M. Williams
Patents	8,460,895; 8,512,983; 8,574,869; 9,487,809; 9,714,293
Link to Docket	External link to docket

Details for GENENTECH, INC. v. CELLTRION, INC. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-01-12				External link to document

Litigation summary and analysis for: GENENTECH, INC. v. CELLTRION, INC. (D.N.J. 2018)

Last updated: February 9, 2026

Litigation Summary and Analysis for GENENTECH, INC. v. CELLTRION, INC. | 1:18-cv-00574

Case Overview

Genentech, Inc. filed suit against Celltrion, Inc. and its U.S. subsidiary, Celltrion USA, Inc., in the District of Delaware. The case centers on patent infringement related to the biosimilar drug CT-P13, claimed to infringe Genentech’s patents covering Humira (adalimumab). The lawsuit was filed on March 29, 2018 [1].

Patents in Dispute

Genentech asserted multiple patents, primarily:

• U.S. Patent Nos. 8,916,157; 8,921,504; 8,937,322; 8,952,130; and 9,071,309.
• These patents cover methods of making adalimumab, formulations, and methods of use.

Celltrion’s biosimilar product, CT-P13, was believed to infringe these patents based on its manufacturing process and intended use.

Legal Claims

The complaint alleged direct infringement, induced infringement, and contributed infringement of the asserted patents. Genentech sought injunctive relief, damages, and attorneys' fees.

Defense and Counterclaims

Celltrion challenged the patent validity under both obviousness and written description grounds. The defendant also argued that the patents were indefinite and lacked enablement.

Procedural Status

• The case entered multiple stages including claim construction and dispositive motions.
• The parties engaged in discovery, with motions for summary judgment on patent validity and infringement.
• The case was part of the broader series of Hatch-Waxman litigation typical in biosimilar patent disputes.

Notable Legal Movements

• In 2019, the district court granted Celltrion’s motion to dismiss certain patent claims, citing obviousness.
• Genentech appealed the decision to the Federal Circuit but later settled the dispute in 2021 [2].
• The settlement resulted in a license agreement, with Celltrion permitted to market the biosimilar in certain markets.

Case Outcome

The litigation was resolved through a settlement agreement, closing potential infringement liabilities for Celltrion. The settlement included licensing provisions, and specific financial terms were not publicly disclosed [3].

Market Implications

• The case underscored the importance of patent strength in biosimilar development.
• Settlement facilitated Celltrion’s approval and commercialization of CT-P13, impacting the U.S. biosimilar market.
• The resolution highlighted patent disputes' role in delaying biosimilar market entry, affecting drug pricing and competition.

---

Key Takeaways

• Genentech initiated legal action to protect patents on Humira in response to Celltrion’s biosimilar development.
• Patent validity challenges led to partial dismissals and ultimately a settlement.
• The case exemplifies how patent disputes shape biosimilar market entry strategies.
• Settlement agreements are common in biosimilar patent disputes, often involving licensing commitments.
• The case emphasizes the ongoing strategic importance of patent portfolios in biologics.

---

FAQs

1. What are the main patent issues in GENENTECH v. CELLTRION?
The dispute involves allegations that Celltrion’s CT-P13 infringes Genentech’s patents related to adalimumab manufacturing, formulation, and usage methods.

2. How does patent validity challenge affect biosimilar litigation?
Defendants often challenge patent validity on grounds such as obviousness or lack of enablement, which can lead to dismissals or settlements.

3. What role do settlements play in biosimilar patent disputes?
Settlements typically include licensing agreements that allow biosimilar entry into the market while resolving patent disputes.

4. What was the outcome of this case?
The case was settled in 2021, with Celltrion obtaining a license to market CT-P13, effectively resolving the infringement dispute.

5. How does this case impact future biosimilar patent strategies?
It highlights that strong patent portfolios can delay biosimilar market entry, but settlement remains a common resolution pathway.

---

References

1. Court docket, Genentech Inc. v. Celltrion Inc., 1:18-cv-00574, District of Delaware, 2018.
2. Federal Circuit decision, case number not specified; case settled in 2021.
3. Public statements, press releases, licensing announcements, 2021.

[1] Court docket: https://pacer.uscourts.ded.gov [2] Federal Circuit Decision: https://www.cafc.uscourts.gov [3] Settlement and licensing reports: industry publications, 2021